Rodin Therapeutics, a Cambridge, MA-based biotechnology company discovering and developing novel therapeutics to boost synaptic resilience, completed a $27m financing round.
The round included returning investor Atlas Venture, with further participation from GV, Hatteras Venture Partners, Remeditex Ventures, and Third Point Ventures. As part of the financing round, John W. Creecy (Remeditex), Jason Hong, Ph.D. (Third Point), and Clay Thorp (Hatteras) joined Rodin’s board of directors.
The company intends to use the funds for the ongoing development of innovative product candidates designed to treat neurological disorders, such as Alzheimer’s disease and Parkinson’s disease.
Led by Adam Rosenberg, President and CEO, Rodin Therapeutics is discovering and developing therapeutics for neurological disorders, applying insights into the role of epigenetics and novel chemical strategies to target specific HDAC complexes. The company’s translational strategy, along with a targeted approach to synaptic resilience, has potential for multiple phenotypically diverse diseases – such as Parkinson’s disease, Alzheimer’s disease, Frontotemporal dementia, post-traumatic stress disorder and traumatic brain injury – which all share the common root cause of impaired neuronal and synaptic function.